<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04143802</url>
  </required_header>
  <id_info>
    <org_study_id>17137</org_study_id>
    <secondary_id>J1I-MC-GZBB</secondary_id>
    <nct_id>NCT04143802</nct_id>
  </id_info>
  <brief_title>A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn about the side effects of LY3437943 when given to
      participants with type 2 diabetes. Blood tests will be performed to investigate how the body
      processes the study drug and how the study drug affects the body. Each enrolled participant
      will receive injections of LY3437943, dulaglutide, or placebo given just under the skin. For
      each participant, the study will last up to about 5 months and will include 16 visits to the
      study center.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2019</start_date>
  <completion_date type="Anticipated">December 11, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 11, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Day 106</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of LY3437943</measure>
    <time_frame>Baseline through study completion (12 weeks)</time_frame>
    <description>PK: AUC of LY3437943</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of LY3437943</measure>
    <time_frame>Baseline through study completion (12 weeks)</time_frame>
    <description>PK: Cmax of LY3437943</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Mean Daily Plasma Glucose (PG)</measure>
    <time_frame>Baseline through Day 80</time_frame>
    <description>Change from baseline in mean daily PG from 6-point PG profile</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LY3437943</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3437943 administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dulaglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dulaglutide administered SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3437943</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3437943</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Dulaglutide</arm_group_label>
    <other_name>LY2189265</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have T2DM for at least 3 months before screening and are without advanced known
             possible complications of diabetes mellitus

          -  Have a glycated hemoglobin (HbA1c) value at lead-in and screening of ≥7.0% and ≤10.5%
             and treated with diet and exercise alone or a stable dose of metformin for at least 3
             months prior to screening

          -  Have had a stable body weight for the 3 months prior to randomization (&lt;5% body weight
             change)

          -  Have a body mass index of 23 to 50 kilograms per square meter (kg/m²), inclusive

          -  Male participants agree to use an effective method of contraception for the duration
             of the study plus 90 days, which corresponds to 4 months after the last
             investigational product dose

          -  Women not of childbearing potential may participate and include those who are:
             infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or
             tubal ligation), congenital anomaly such as mullerian agenesis; or those who are
             postmenopausal

        Exclusion Criteria:

          -  Have type 1 diabetes mellitus or latent autoimmune diabetes in adults

          -  Have uncontrolled diabetes, defined as an episode of ketoacidosis or hyperosmolar
             state requiring hospitalization in the 6 months prior to screening

          -  Have a known clinically significant gastric emptying abnormality

          -  Have had an episode of severe hypoglycemia

          -  Have a history of acute or chronic pancreatitis or fasting serum triglyceride level of
             &gt;500 milligrams per deciliter (mg/dL) at screening and/or Day‒2. If participant is on
             lipid-lowering therapies, doses must be stable for 30 days prior to screening

          -  Have known liver disease, obvious clinical signs or symptoms of liver disease, acute
             or chronic hepatitis, or have elevations in aminotransferases (alanine
             aminotransferase [ALT] and aspartate aminotransferase [AST]) greater than 3X upper
             limit of normal (ULN) at screening and/or Day -2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-774-7777</phone>
    </contact>
    <investigator>
      <last_name>Amina Z Haggag</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>305-665-5151</phone>
    </contact>
    <investigator>
      <last_name>Martha Hernandez-Illas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>913-259-7100</phone>
    </contact>
    <investigator>
      <last_name>Daniel S Dickerson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>210-949-0122</phone>
    </contact>
    <investigator>
      <last_name>Douglas S. Denham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/adult-type-2-diabetes/GZBB#?postal=</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 1, 2020</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

